Trial Profile
Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms NEARQD
- 13 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 May 2019.
- 15 Nov 2018 New trial record